section name header

Pronunciation

IN-su-lin GLAR-jeen

Classifications

Therapeutic Classification: hormones, antidiabetics

Pharmacologic Classification: pancreatics

Indications

High Alert


Action

  • Lowers blood glucose by:
    • stimulating glucose uptake in skeletal muscle and fat;
    • inhibiting hepatic glucose production.
  • Other actions of insulin:
    • inhibition of lipolysis and proteolysis;
    • enhanced protein synthesis.
Therapeutic effects:
  • Control of hyperglycemia in patients with type 1 or type 2 diabetes.

Pharmacokinetics

Absorption: Provides slower prolonged absorption and a relatively constant concentrations over 24 hr.

Distribution: Identical to endogenous insulin.

Metabolism/Excretion: Partially metabolized at the site of injection to active insulin metabolites. Metabolized by liver, spleen, kidney, muscle.

Half-Life: 5–6 min (prolonged in diabetic patients; biological half-life is longer).

Time/Action Profile

(hypoglycemic effect)

ROUTEONSETPEAKDURATION
SUBQ3–4 hrnone24 hr



Small amounts of insulin glargine are slowly released resulting in a relatively constant effect over time.



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Endo: HYPOGLYCEMIA

F and E: hypokalemia

Local: cutaneous amyloidosis, lipodystrophy, pruritus, erythema, swelling

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Toujeo has a lower glucose lowering effect than Basaglar, Rezvoglar, or Semglee on a unit-to-unit basis.

Basaglar, Rezvoglar, or Semglee

Toujeo

Availability

Assessment

Lab Test Considerations:

Toxicity and Overdose:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Basaglar KwikPen, Basaglar Tempo Pen, Lantus, Lantus SoloStar, Rezvoglar KwikPen, Semglee, Toujeo Max SoloStar, Toujeo SoloStar

Pill Image

insulinglargine_195-8887.jpg